cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.20329134
title: Supplementary Material for: DPP4 Inhibitor-Induced Bullous Pemphigoid in Patients with Diabetes and Chronic Kidney Disease: Clinical Case Series

description: <b><i>Introduction:</i></b> Dipeptidyl peptidase-4 (DPP4) inhibitors (gliptins) are commonly prescribed for glucose control in patients with advanced chronic kidney disease (CKD) in whom other oral glucose-lowering agents are contraindicated. In the past few years, new reports of drug-induced bullous pemphigoid associated with DPP4 inhibitors have emerged. However, there is not enough information about the renal function of the patients with DPP4 inhibitor-induced bullous pemphigoid, and it remains unknown whether the risk of this complication is increased among patients with CKD. <b><i>Case Reports:</i></b> Five patients with stage 3b-5 CKD received a diagnosis of DPP4 inhibitor-associated bullous pemphigoid in our institution within a period of 17 months (between December 2018 and May 2020). All patients in the current series were male. Skin biopsies were performed in all patients. Three cases were secondary to vildagliptin, and 2 cases were attributed to linagliptin. In each of these patients, treatment consisted of permanent discontinuation of the DPP4 inhibitor and administration of corticosteroids. <b><i>Conclusion:</i></b> We report here the first single-center experience of DPP4 inhibitor-induced bullous pemphigoid in patients with CKD. Our case series highlights the importance of considering bullous pemphigoid in patients with CKD taking DPP4 inhibitors presenting with bullous or pruritic cutaneous lesions. By calling attention to this important complication, we hope to minimize the delay in diagnosing DPP4 inhibitor-induced bullous pemphigoid among patients with CKD.
DOI: 10.6084/m9.figshare.20329134.v1
title: Supplementary Material for: DPP4 Inhibitor-Induced Bullous Pemphigoid in Patients with Diabetes and Chronic Kidney Disease: Clinical Case Series

description: <b><i>Introduction:</i></b> Dipeptidyl peptidase-4 (DPP4) inhibitors (gliptins) are commonly prescribed for glucose control in patients with advanced chronic kidney disease (CKD) in whom other oral glucose-lowering agents are contraindicated. In the past few years, new reports of drug-induced bullous pemphigoid associated with DPP4 inhibitors have emerged. However, there is not enough information about the renal function of the patients with DPP4 inhibitor-induced bullous pemphigoid, and it remains unknown whether the risk of this complication is increased among patients with CKD. <b><i>Case Reports:</i></b> Five patients with stage 3b-5 CKD received a diagnosis of DPP4 inhibitor-associated bullous pemphigoid in our institution within a period of 17 months (between December 2018 and May 2020). All patients in the current series were male. Skin biopsies were performed in all patients. Three cases were secondary to vildagliptin, and 2 cases were attributed to linagliptin. In each of these patients, treatment consisted of permanent discontinuation of the DPP4 inhibitor and administration of corticosteroids. <b><i>Conclusion:</i></b> We report here the first single-center experience of DPP4 inhibitor-induced bullous pemphigoid in patients with CKD. Our case series highlights the importance of considering bullous pemphigoid in patients with CKD taking DPP4 inhibitors presenting with bullous or pruritic cutaneous lesions. By calling attention to this important complication, we hope to minimize the delay in diagnosing DPP4 inhibitor-induced bullous pemphigoid among patients with CKD.
DOI: 10.6084/m9.figshare.20329125
title: UDAMP_database

description: This is the electronic version of the updated UDAMP database
DOI: 10.6084/m9.figshare.20329116
title: Laccase PSE files

description: Plant laccase structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20329116.v1
title: Laccase PSE files

description: Plant laccase structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20329092
title: Catechol oxidases PSE files

description: Plant catechol oxidases structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20329092.v1
title: Catechol oxidases PSE files

description: Plant catechol oxidases structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20329056
title: Catechol oxidases PDB files

description: Plant catechol oxidases structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20329056.v1
title: Catechol oxidases PDB files

description: Plant catechol oxidases structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20219841
title: Laccase PDB files

description: Plant laccase structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20219841.v1
title: Laccase PDB files

description: Plant laccase structures predicted by AlphaFold2 with parameters( --db_preset=full_dbs --model_preset=monomer_casp14) and chose ranked_0.pdb file.
DOI: 10.6084/m9.figshare.20329164
title: Supplementary Material for: Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients

description: The optimal SARS-CoV-2 vaccination schedule in dialysis patients and the potential need for a fourth vaccine dose are debatable. We prospectively assessed the humoral responses to three and four doses of BNT162b2 among dialysis patients. The study included 106 dialysis patients; 60 (56.6%) and 46 (43.4%) received 3 and 4 vaccine doses, respectively. Anti-spike (anti-S) antibody titers significantly increased after the third vaccine dose, followed by a decline, yet still remained higher than all previous measurements. The fourth vaccine dose led to another profound rise in anti-S titers. The absolute increase following the fourth dose correlated with response to the third dose. Infection risk however was similar between patients vaccinated with three or four doses.
DOI: 10.6084/m9.figshare.20329170
title: Supplementary tables in mice

description: Supplementary table 1 Metabolic set KEGG pathway statistics on Conv mice Supplementary table 2 Metabolic set KEGG pathway statistics on GF mice Supplementary table 3 Serum metabolites profile of high-salt diet on Conv mice Supplementary table 4 Serum metabolites profile of high-salt diet on GF mice Supplementary table 5 Serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on high-salt induced Conv mice Supplementary table 6 Metabolites mapped to the KEGG pathway on Conv mice Supplementary table 7 Metabolites mapped to the KEGG pathway on GF mice Supplementary table 8 Serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on high-salt induced GF mice Supplementary table 9 Common serum metabolites profile of high-salt diet on Conv and GF mice Supplementary table 10 Special serum metabolites profile of high-salt diet on Conv mice Supplementary table 11 Special serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on Conv mice Supplementary table 12 Special serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on GF mice Supplementary table 13 Special serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on Conv mice
DOI: 10.6084/m9.figshare.20329170.v1
title: Supplementary tables in mice

description: Supplementary table 1 Metabolic set KEGG pathway statistics on Conv mice Supplementary table 2 Metabolic set KEGG pathway statistics on GF mice Supplementary table 3 Serum metabolites profile of high-salt diet on Conv mice Supplementary table 4 Serum metabolites profile of high-salt diet on GF mice Supplementary table 5 Serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on high-salt induced Conv mice Supplementary table 6 Metabolites mapped to the KEGG pathway on Conv mice Supplementary table 7 Metabolites mapped to the KEGG pathway on GF mice Supplementary table 8 Serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on high-salt induced GF mice Supplementary table 9 Common serum metabolites profile of high-salt diet on Conv and GF mice Supplementary table 10 Special serum metabolites profile of high-salt diet on Conv mice Supplementary table 11 Special serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on Conv mice Supplementary table 12 Special serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on GF mice Supplementary table 13 Special serum metabolites profile of <em>Dubosiella newyorkensis</em> (NYU-BL-A4) on Conv mice
DOI: 10.15151/esrf-es-879022036
title: (U)SAXS measurement on protein aggregates

description: USAXS measurement on protein aggregates from pei and whey, at different concentration and varying the aggregation process
DOI: 10.15151/esrf-es-883598359
title: 3DXRD of iron wire

description: 3DXRD of iron wire and investigation of harmonics
DOI: 10.15151/esrf-es-879295211
title: XAS/XES and RIXS measurements on different 3d metals (Cu, Ni, Fe) compounds for different applications.

description: This proposal involves 3 different projects: 1) XAS/XES and RIXS preliminary study of the interaction of a novel Cu-phenanthroline chemotherapeutic with bio-molecules during x-ray excitation. The experiments aim to characterize the electronic structure around the Cu metal centers and possibly predict a chemical action mechanism in cancer cells. 2) XAS measurement of NiO, Ni(OH)2, and NiSO4 hexahydrate references as ex situ pellet and liquid jet. The data will help in the interpretation of previous Ni K-edge XANES spectra collected on oh-PtNiIr nanoparticles in a proton exchange membrane fuel cell. 3) XAS/XES ex situ measurements Pt-CaTi1-xFexO3-d (CTF) perovskite catalyst.The introduction of Fe atoms in improves the catalytic performance in the context of the low temperature oxidation of CO.However, the catalytic role and oxidation state of the Fe is still not completely understood.The experiment aim to unveil the electronic structure and local coordination geometry of the Fe atoms.
DOI: 10.6084/m9.figshare.20329149
title: Supplementary Table S6

description: Differential peaks annotation of fibroblasts
DOI: 10.6084/m9.figshare.20329149.v1
title: Supplementary Table S6

description: Differential peaks annotation of fibroblasts
DOI: 10.6084/m9.figshare.20329152
title: Supplementary Table S7

description: Differential peaks annotation of keratinocytes.
DOI: 10.6084/m9.figshare.20329143
title: Supplementary Table S5

description: Differential peaks of keratinocytes.
DOI: 10.6084/m9.figshare.20329128
title: Supplementary Table S2

description: Top 20 accessible genes in E16.5 mice skin.
DOI: 10.6084/m9.figshare.20329137
title: Supplementary Table S3

description: Top 20 accessible genes in P0 mice skin.
DOI: 10.6084/m9.figshare.20329140.v1
title: Supplementary Table S4

description: Differential peaks of fibroblasts.
DOI: 10.6084/m9.figshare.20329128.v1
title: Supplementary Table S2

description: Top 20 accessible genes in E16.5 mice skin.
DOI: 10.6084/m9.figshare.20329122
title: Supplementary Table S1

description: Top 20 accessible genes in E13.5 mice skin.
DOI: 10.6084/m9.figshare.20329137.v1
title: Supplementary Table S3

description: Top 20 accessible genes in P0 mice skin.
DOI: 10.6084/m9.figshare.20329122.v1
title: Supplementary Table S1

description: Top 20 accessible genes in E13.5 mice skin.
DOI: 10.6084/m9.figshare.20329140
title: Supplementary Table S4

description: Differential peaks of fibroblasts.
DOI: 10.6084/m9.figshare.20329143.v1
title: Supplementary Table S5

description: Differential peaks of keratinocytes.
DOI: 10.6084/m9.figshare.18461762
title: MJ20201224061.zip

description: microbiology
DOI: 10.6084/m9.figshare.18461762.v1
title: MJ20201224061.zip

description: microbiology
DOI: 10.34740/kaggle/dsv/3955583
title: KNNdata
DOI: 10.25442/hku.20059676
title: Supporting data for "Reconstruction and Motion Correction for Multi-Shot Diffusion-Weighted Magnetic Resonance Imaging"

description: Diffusion-weighted imaging (DWI) is a promising research area and has been widely used in clinical applications. However, DWI is very vulnerable to motion artifacts. Multiple motion correction methods are investigated in this study. Furthermore, a novel iblocks-DWI protocol has been developed and implemented for 2D and 3D DWI imaging. Motion correction methods were developed accordingly. This novel iblocks-DWI protocol has been compared with the conventional navigated interleaved DWI protocol. Performances of motion correction methods were evaluated. <br> This dataset contains the code, raw data, and results of four projects related to motion correction of multi-shot diffusion-weighted imaging. In the first project, several motion correction methods were used for readout-segmented DWI data, and the performances were compared. The second project evaluated the use of four-shot DWI in liver. MUSE and SENSE were used for data reconstruction and minuscule motion correction. The third project proposed motion correction algorithms for 2D blocks DWI and DTI. The forth project discussed reconstruction and motion correction for 3D blocks DWI.
DOI: 10.25442/hku.20059676.v2
title: Supporting data for "Reconstruction and Motion Correction for Multi-Shot Diffusion-Weighted Magnetic Resonance Imaging"

description: Diffusion-weighted imaging (DWI) is a promising research area and has been widely used in clinical applications. However, DWI is very vulnerable to motion artifacts. Multiple motion correction methods are investigated in this study. Furthermore, a novel iblocks-DWI protocol has been developed and implemented for 2D and 3D DWI imaging. Motion correction methods were developed accordingly. This novel iblocks-DWI protocol has been compared with the conventional navigated interleaved DWI protocol. Performances of motion correction methods were evaluated. <br> This dataset contains the code, raw data, and results of four projects related to motion correction of multi-shot diffusion-weighted imaging. In the first project, several motion correction methods were used for readout-segmented DWI data, and the performances were compared. The second project evaluated the use of four-shot DWI in liver. MUSE and SENSE were used for data reconstruction and minuscule motion correction. The third project proposed motion correction algorithms for 2D blocks DWI and DTI. The forth project discussed reconstruction and motion correction for 3D blocks DWI.
DOI: 10.25442/hku.20059676.v1
title: Supporting data for "Motion Correction for Multi-Shot Diffusion-Weighted Magnetic Resonance Imaging"

description: Diffusion-weighted imaging (DWI) is a promising research area and has been widely used in clinical applications. However, DWI is very vulnerable to motion artifacts. Multiple motion correction methods are investigated in this study. Furthermore, a novel iblocks-DWI protocol has been developed and implemented for 2D and 3D DWI imaging. Motion correction methods were developed accordingly. This novel iblocks-DWI protocol has been compared with the conventional navigated interleaved DWI protocol. Performances of motion correction methods were evaluated. <br> This dataset contains the code, raw data, and results of four projects related to motion correction of multi-shot diffusion-weighted imaging. In the first project, several motion correction methods were used for readout-segmented DWI data, and the performances were compared. The second project evaluated the use of four-shot DWI in liver. MUSE and SENSE were used for data reconstruction and minuscule motion correction. The third project proposed motion correction algorithms for 2D blocks DWI and DTI. The forth project discussed reconstruction and motion correction for 3D blocks DWI.
DOI: 10.48544/df8ffa76-26f4-407e-998a-f584c7d25201
title: Complexity Theory (web lectures)
DOI: 10.5281/zenodo.6801927
title: Lymphoscintigraphy results of patients with limb lymphostasis

description: The database contains the lymphoscintigraphy results of the extremities, which are distributed according to the stages of lymphostasis. All images are presented in DiCOM format.
DOI: 10.5281/zenodo.6801926
title: Lymphoscintigraphy results of patients with limb lymphostasis

description: The database contains the lymphoscintigraphy results of the extremities, which are distributed according to the stages of lymphostasis. All images are presented in DiCOM format.
DOI: 10.25442/hku.20222109
title: Supporting data for "Chloride resistance of alkali-activated slag: mechanism and improvement"

description: Alkali-activated slag (AAS) is a promising green alternative to traditional ordinary Portland cement (OPC) with a potentially lower carbon footprint. Despite the reported satisfying mechanical performance, there remain certain unknowns about the durability performance of AAS in aggressive environments, which hinders its industrial acceptance and practical application. This thesis aims to understand the degradation mechanism of AAS upon chloride attack from complex marine environments and examine different strategies for improving the chloride resistance of AAS. This dataset is the supporting data for the thesis entitled “Chloride resistance of alkali-activated slag: mechanism and improvement”. There are four sub-folders in this dataset: Folder 1: Supporting data for chapter 3 This folder contains the raw and processed data for the chloride resistance of AAS and OPC in seawater as shown in chapter 3. <br> Folder 2: Supporting data for chapter 4 This folder contains the raw and processed data for the chloride resistance of AAS with corrosion inhibitors as shown in chapter 4. <br> Folder 3: Supporting data for chapter 5 This folder contains the raw and processed data for the chloride binding of AAS with mineral additives as shown in chapter 5. <br> Folder 4: Supporting data for chapter 6 This folder contains the raw and processed data for the chloride resistance of sodium carbonate-activated slag modified with mineral additives as shown in chapter 6.
DOI: 10.25442/hku.20222109.v1
title: Supporting data for "Chloride resistance of alkali-activated slag: mechanism and improvement"

description: Alkali-activated slag (AAS) is a promising green alternative to traditional ordinary Portland cement (OPC) with a potentially lower carbon footprint. Despite the reported satisfying mechanical performance, there remain certain unknowns about the durability performance of AAS in aggressive environments, which hinders its industrial acceptance and practical application. This thesis aims to understand the degradation mechanism of AAS upon chloride attack from complex marine environments and examine different strategies for improving the chloride resistance of AAS. This dataset is the supporting data for the thesis entitled “Chloride resistance of alkali-activated slag: mechanism and improvement”. There are four sub-folders in this dataset: Folder 1: Supporting data for chapter 3 This folder contains the raw and processed data for the chloride resistance of AAS and OPC in seawater as shown in chapter 3. <br> Folder 2: Supporting data for chapter 4 This folder contains the raw and processed data for the chloride resistance of AAS with corrosion inhibitors as shown in chapter 4. <br> Folder 3: Supporting data for chapter 5 This folder contains the raw and processed data for the chloride binding of AAS with mineral additives as shown in chapter 5. <br> Folder 4: Supporting data for chapter 6 This folder contains the raw and processed data for the chloride resistance of sodium carbonate-activated slag modified with mineral additives as shown in chapter 6.
DOI: 10.25442/hku.20193437
title: Supporting data for BISMUTH-BASED DRUGS AND AGENTS AS ANTI-SARS-COV-2 AGENTS AND NEPHROTOXICITY SCAVENGERS

description: Metal compounds have long been used in clinic for the treatment and diagnosis of various diseases (e.g., platinum-based anti-cancer drugs, bismuth-based anti-ulcer drugs and gadolinium-based MRI imaging) and have enormous potential for emerging infectious diseases. For example, COVID-19 pandemic unprecedently triggers global public health issue while effective treatment options remain limited. Collectively, these findings validate the potential to expedite the development of bismuth (III) based agents and provide novel insights into the molecular basis of metallodrugs and stimulate translational research to flourish.
DOI: 10.25442/hku.20193437.v1
title: Supporting data for BISMUTH-BASED DRUGS AND AGENTS AS ANTI-SARS-COV-2 AGENTS AND NEPHROTOXICITY SCAVENGERS

description: Metal compounds have long been used in clinic for the treatment and diagnosis of various diseases (e.g., platinum-based anti-cancer drugs, bismuth-based anti-ulcer drugs and gadolinium-based MRI imaging) and have enormous potential for emerging infectious diseases. For example, COVID-19 pandemic unprecedently triggers global public health issue while effective treatment options remain limited. Collectively, these findings validate the potential to expedite the development of bismuth (III) based agents and provide novel insights into the molecular basis of metallodrugs and stimulate translational research to flourish.
DOI: 10.57770/va5xmx
title: Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer.

description: Purpose: In head and neck squamous cell carcinoma (HNSCC), the incidence of RAS mutation, which is the major cause of cetuximab resistance, is relatively rare compared with the other types of cancers, and the mechanism mediating acquired resistance is unclear compared with the driver gene mutation-mediated de novo resistance. Here, we investigated the driver gene mutation-independent mechanism for cetuximab resistance in HNSCC.Experimental Design: We used the in vitro-selected and in vivo-selected cetuximab-resistant sublines of HNSCC cell lines for investigating the mechanism of acquired resistance to cetuximab. Zebrafish model was applied for evaluating the synergistic effect of combinatory drugs for overcoming cetuximab resistance.Results: The cetuximab-resistant HNSCC cells undergo a Snail-induced epithelial-mesenchymal transition. Mechanistically, Snail induces the expression of lymphotoxin-β (LTβ), a TNF superfamily protein that activates NF-κB, and protein arginine methyltransferase 1 (PRMT1), an arginine methyltransferase that methylates EGFR. LTβ interacts with methylated EGFR to promote its ligand-binding ability and dimerization. Furthermore, LTβ activates the NF-κB pathway through a LTβ receptor-independent mechanism. Combination of an EGFR tyrosine kinase inhibitor and a NF-κB inhibitor effectively suppressed cetuximab-resistant HNSCC and interfering with the EGFR-LTβ interaction reverses resistance.Conclusions: Our findings elucidate the mechanism of driver gene mutations-independent mechanism of acquired resistance to cetuximab in HNSCC and also provide potential strategies for combating cetuximab resistance. Clin Cancer Res; 23(15); 4388-401. ©2017 AACR.